



## Conference on ‘Nutrition and healthy ageing’ The 2013 Summer Meeting Postgraduate Winners

### B-vitamins and bone in health and disease: the current evidence

M. Clarke<sup>1</sup>, M. Ward<sup>1</sup>, J. J. Strain<sup>1</sup>, L. Hoey<sup>1</sup>, W. Dickey<sup>2</sup> and H. McNulty<sup>1\*</sup>

<sup>1</sup>Northern Ireland Centre for Food and Health, University of Ulster, Coleraine BT52 1SA, UK

<sup>2</sup>Department of Gastroenterology, Altnagelvin Hospital, Londonderry BT47 6SB, UK


Osteoporosis, a metabolic skeletal disease characterised by decreased bone mass and increased fracture risk, is a growing public health problem. Among the various risk factors for osteoporosis, calcium and vitamin D have well-established protective roles, but it is likely that other nutritional factors are also implicated. This review will explore the emerging evidence supporting a role for certain B-vitamins, homocysteine and the 677C→T polymorphism in the gene encoding the folate-metabolising enzyme methylenetetrahydrofolate reductase, in bone health and disease. The evidence, however, is not entirely consistent and as yet no clear mechanism has been defined to explain the potential link between B-vitamins and bone health. Coeliac disease, a common condition of malabsorption, induced by gluten ingestion in genetically susceptible individuals, is associated with an increased risk both of osteoporosis and inadequate B-vitamin status. Given the growing body of evidence linking low bone mineral density and/or increased fracture risk with low B-vitamin status and elevated homocysteine, optimal B-vitamin status may play an important protective role against osteoporosis in coeliac disease; to date, no trial has addressed this possible link.

#### B-vitamins: homocysteine: MTHFR 677C→T polymorphism: bone: coeliac disease

Osteoporosis, a metabolic skeletal disease characterised by reduced bone mass and deterioration of bone micro-architecture, predisposes affected individuals to an increased risk of fragility fracture<sup>(1)</sup>. It is a major public health problem, recently estimated to cost £5.5 billion in the UK alone<sup>(2)</sup>, with one in two women and one in five men over the age of 50 years expected to experience an osteoporotic fracture<sup>(3)</sup>. Bone is a dynamic tissue in a constant state of remodelling. Bone formation generally outweighs bone resorption in the first three decades of life, and peak bone mass (i.e. the maximum bone mass achieved in adulthood) is accrued during this period. After this time, bone resorption is favoured and bone loss ensues, which in turn predisposes older individuals to weaker bones and increased risk of fracture<sup>(4)</sup>. The most common osteoporotic fracture sites are at the spine, hip and wrist, with both spine and hip fractures accompanied by considerable disability and increased morbidity and mortality<sup>(5)</sup>.

The measurement of bone mineral density (BMD) through dual-energy X-ray absorptiometry scanning is currently the basis of diagnosing osteoporosis. The WHO defines osteoporosis as a BMD of less than or equal to 2.5 SD below the reference mean of a young adult with peak bone mass (i.e. a *T*-score of  $\leq -2.5$  SD), and osteopenia (the precursor stage to osteoporosis) as a BMD of less than 1 SD but greater than 2.5 SD below the reference mean (i.e. a *T*-score between  $-1$  and  $-2.5$  SD)<sup>(6)</sup>. A BMD greater than or equal to 1 SD below the reference mean is defined as normal (i.e. a *T*-score of  $\geq -1$  SD) according to the WHO criteria<sup>(6)</sup>. Each SD fall in BMD (i.e. per unit *T*-score) below the reference mean corresponds to an estimated 2-fold increase in fracture risk<sup>(7,8)</sup>. While low BMD is an important predictor of osteoporosis, fracture incidence is the most important clinical end point for osteoporosis. In recent years, the FRAX<sup>®</sup> tool, an algorithm used to assess the fracture probability by integrating weighted clinical risk

**Abbreviations:** BMD, bone mineral density; CD, coeliac disease; MTHFR, methylenetetrahydrofolate reductase; RCT, randomised controlled trials.  
**\*Corresponding author:** Professor H. McNulty, fax +44 28 70124965, email h.mcnulty@ulster.ac.uk



**Fig. 1.** (Colour online) The metabolism of homocysteine. MTHFR, methylenetetrahydrofolate reductase; DMG, dimethylglycine.

factors of disease (with or without BMD), was developed by the WHO and has been used to assess osteoporotic fracture risk<sup>(9)</sup>.

The aetiology of osteoporosis is multi-factorial, with genetic heritability estimated to account for approximately 30% of osteoporotic fracture risk<sup>(10)</sup>. Non-modifiable factors including age, parental history of hip fracture and genetically determined traits, such as Caucasian ethnicity and female sex, increase risk<sup>(2)</sup>. Similarly, various modifiable factors such as low body weight, physical inactivity, smoking, excessive alcohol intake and the long-term use of certain medications (e.g. glucocorticoids and some anti-convulsant drugs) increase the risk of osteoporosis. Considering the general trend towards ageing populations, and the corresponding increases in osteoporosis-related costs<sup>(2)</sup>, investigation of modifiable risk factors, along with the development of intervention strategies to reduce the incidence of disease, is vital. In terms of nutritional intervention, combined calcium and vitamin D supplementation are proven to reduce bone loss and fracture incidence<sup>(11)</sup>. However, it is also possible that the nutritional factors not typically linked to bone health could play protective roles. Emerging evidence in generally healthy cohorts worldwide suggests a protective effect of certain B-vitamins, and a detrimental effect of homocysteine and the 677C→T

polymorphism in the gene encoding the folate-metabolising enzyme methylenetetrahydrofolate reductase (MTHFR), on bone health and fracture risk<sup>(12,13)</sup>.

#### Role of B-vitamins in homocysteine metabolism

The major determinant of plasma homocysteine concentration is the biomarker status of the metabolically related B-vitamins, primarily folate, and to lesser extent vitamins B<sub>12</sub> and B<sub>6</sub> (Fig. 1). Homocysteine is formed by the demethylation of dietary methionine. Homocysteine may then be metabolised to form cystathionine as the part of the trans-sulphuration pathway, requiring a vitamin B<sub>6</sub> co-factor, or regenerate methionine, and in turn S-adenosyl methionine (a universal methyl donor). The latter reaction is catalysed by methionine synthase and requires 5-methyltetrahydrofolate, the principal circulating form of folate and vitamin B<sub>12</sub> in its co-factor form, methylcobalamin. The formation of 5-methyltetrahydrofolate is catalysed by the enzyme MTHFR, which has the riboflavin-derived FAD as a prosthetic group. Supplementation with folic acid can lower homocysteine concentrations by an estimated 25%, with vitamins B<sub>12</sub> and B<sub>6</sub> having additional homocysteine lowering effects (i.e. by a further 7% each) in

**Table 1.** Observational evidence to support a role for homocysteine (Hcy) and B-vitamin status in fracture risk

Author, Country	Sample size, age, gender	Design	Main findings; Risk of fracture (95 % CI)
Van Wijngaarden <i>et al.</i> <sup>(12)</sup> , International	<i>n</i> 11 511, NA, male/female	Meta-analysis; eight studies	RR 1.04 (1.02, 1.07) per 1 µmol/l increase in Hcy
Dai <i>et al.</i> <sup>(29)</sup> , Singapore	<i>n</i> 63 257, 45–74 years, male/female	Cohort study	HR 0.78 (0.66, 0.93) in women in the highest quartile intake of pyridoxine compared with the lowest
Yang <i>et al.</i> <sup>(30)</sup> , International	<i>n</i> 14 863, NA, male/female	Meta-analysis; nine studies	RR 1.59 (1.30, 1.96) and 1.67 (1.17, 2.38) for all fractures and hip fractures, respectively, in highest Hcy quartile compared with lowest
Enneman <i>et al.</i> <sup>(31)</sup> , The Netherlands	<i>n</i> 503, ≥55 years, female	Cohort study	Incidence of fracture was associated with increasing Hcy quartile, <i>P</i> =0.047
LeBoff <i>et al.</i> <sup>(32)</sup> , USA	<i>n</i> 800, mean 70 years, female	Case-control study	OR 1.38 (1.14, 1.66) at hip, per SD increase in serum Hcy
Gjesdal <i>et al.</i> <sup>(33)</sup> , Norway	<i>n</i> 4766, 65–67 years, male/female	Prospective study	HR 2.42 (1.43, 4.09) in women and 1.37 (0.63, 2.98) in men with Hcy ≥15 µmol/l compared with ≤9 µmol/l. HR 2.40 (1.50, 3.84) in women with low compared with high folate status
Yazdanpanah <i>et al.</i> <sup>(34)</sup> , The Netherlands	<i>n</i> 5304, ≥55 years, male/female	Cohort study	HR 0.58 (0.38, 0.90) in women in the highest quartile intake of pyridoxine compared with the lowest
Dhonukshe-Rutten <i>et al.</i> <sup>(35)</sup> , The Netherlands	<i>n</i> 1252, ≥65 years, male/female	Prospective study	RR 3.80 (1.20, 11.60) in men and 2.80 (1.30, 5.70) in women with high Hcy and low B <sub>12</sub> compared with normal concentrations.
Van Meurs <i>et al.</i> <sup>(36)</sup> , The Netherlands	<i>n</i> 2406, ≥55 years, male/female	Cohort study	RR 1.40 (1.20, 1.60) per SD increase in log Hcy concentrations. RR 2.00 (1.40, 2.70) for fracture in highest Hcy quartile compared with the lower quartiles
McLean <i>et al.</i> <sup>(37)</sup> , USA	<i>n</i> 1999, 55–91 years, male/female	Cohort study	HR 3.84 (1.38, 10.70) in men and 1.92 (1.18, 3.10) in women, for highest Hcy quartile compared with the lowest quartile

NA, not applicable; RR, relative risk; HR, hazard ratio.

folate replete, and folate and riboflavin replete individuals, respectively<sup>(14,15)</sup>.

The 677C→T polymorphism in *MTHFR* is widely reported as the most common genetic determinant of mildly elevated plasma homocysteine concentrations in healthy populations<sup>(16)</sup>. Individuals with the homozygous mutant TT genotype experience a decrease in *MTHFR* enzyme activity, believed to be through the loss of FAD<sup>(17)</sup>, leading to hyperhomocysteinemia (>15 µmol/l)<sup>(18,19)</sup> and low erythrocyte folate concentrations<sup>(19,20)</sup>. Riboflavin supplementation has however been shown to significantly lower homocysteine concentrations specifically in individuals with the *MTHFR* 677TT genotype<sup>(21)</sup>. The frequency of the *MTHFR* 677TT genotype varies greatly worldwide, ranging from 4 to 18% in the US populations, 10% in many European populations and up to 32% in Mexico<sup>(22,23)</sup>.

Hyperhomocysteinemia mainly reflects low or deficient status of the relevant B-vitamins, or the *MTHFR* genotype, but it can also reflect a decline in renal function with age<sup>(24)</sup>.

## B-vitamins, homocysteine and bone health

### Historical evidence

Homocystinuria, a rare autosomal recessive disease, is a condition in which the metabolism of homocysteine is severely impaired leading to excessive accumulation of homocysteine in the blood (>100 µmol/l) and urine<sup>(25)</sup>. The most common cause of homocystinuria is

cystathionine-β-synthase deficiency. Among the major clinical features of the disease (including mental retardation and severe occlusive vascular disease) premature osteoporosis is well described, and homocystinuric patients are reported to have a 50% increased risk of developing osteoporosis by the age of 16<sup>(25)</sup>. This premature onset of osteoporosis lends support to the hypothesis that mild elevations of homocysteine (and/or impaired status of related B-vitamins), may play a role in the aetiology of osteoporosis in the general population<sup>(26)</sup>.

Early studies in patients with pernicious anaemia provided the first evidence to support a specific role for vitamin B<sub>12</sub> deficiency in osteoporosis. One small study in post-menopausal women with pernicious anaemia (*n* 21) reported lower BMD in patients compared with controls<sup>(27)</sup>. Further evidence from a slightly larger cohort of post-menopausal women (*n* 131) demonstrated an almost 3-fold increase in the risk of osteoporotic fracture among pernicious anaemia patients compared with the general community<sup>(28)</sup>.

### Evidence from observational studies

In the past decade, numerous large observational studies have provided evidence to support a role for homocysteine and/or low B-vitamin status in fracture risk (Table 1)<sup>(12,29–37)</sup>. In 2004, two landmark studies performed in the Netherlands and the USA produced consistent findings in terms of the magnitude of increased risk of fracture associated with mild elevations in homocysteine<sup>(36,37)</sup>. In subsequent years, further studies from

**Table 2.** Observational evidence to support a role for homocysteine (Hcy) and B-vitamin status in low bone mineral density (BMD) and bone loss

Author, Country	Sample size, age, gender	Design	Main findings
Kim <i>et al.</i> <sup>(38)</sup> , Korea	<i>n</i> 460, ≥30 years, male/female	Longitudinal study	Significantly greater bone loss in highest Hcy quartile compared with lowest in pre-menopausal women and men
Zhu <i>et al.</i> <sup>(39)</sup> , Australia	<i>n</i> 1213, 70–85 years, female	Longitudinal study	Significantly greater bone loss in highest Hcy tertile compared with the middle and lowest
Gjesdal <i>et al.</i> <sup>(40)</sup> , Norway	<i>n</i> 5329, 47–50, 71–75 years, male/female	Cohort study	OR 2.19 (95 % CI 1.48, 3.25) and 1.55 (95 % CI 1.07, 2.23) for low BMD among subjects in highest quartile compared with lowest quartile of Hcy and lowest quartile compared with highest quartile of folate, respectively, in women only
McLean <i>et al.</i> <sup>(41)</sup> , USA	<i>n</i> 714, mean 75 years, male/female	Longitudinal study	Participants with deficient plasma vitamin B <sub>6</sub> (<20 nmol/l) had greater mean bone loss compared with those with normal status
Morris <i>et al.</i> <sup>(42)</sup> , USA	<i>n</i> 1550, >55 years, male/female	Cohort study	Serum vitamin B <sub>12</sub> related to BMD in a dose response fashion to 220 pmol/l. Hcy level (≥20 μmol/l) compared with low level (<10 μmol/l) associated with lower BMD
Tucker <i>et al.</i> <sup>(43)</sup> , USA	<i>n</i> 2576, mean 58 years, male/female	Cohort study	Low vitamin B <sub>12</sub> (<148 pmol/l) associated with lower average BMD than those with vitamin B <sub>12</sub> above this cut-off
Cagnacci <i>et al.</i> <sup>(44)</sup> , Italy	<i>n</i> 161, mean 53 years, female	Cross-sectional study	Folate but not Hcy/B <sub>12</sub> , was associated with BMD

the USA, the Netherlands and Norway similarly demonstrated increases in fracture risk associated with elevated homocysteine concentrations<sup>(31–33,35)</sup>. Confirming these findings, a recent meta-analysis involving nine prospective studies and 14863 participants reported a relative risk of 1.59 (95 % CI 1.30, 1.96) and 1.67 (95 % CI 1.17, 2.38) for all fractures and hip fractures, respectively, in those within the highest homocysteine quartile compared with the lowest<sup>(30)</sup>. Most recently, a dose–response meta-analysis including eight observational studies and 11 511 participants estimated a 4 % increase in fracture risk for every 1 μmol/l increase in homocysteine concentration<sup>(12)</sup>. Given the close metabolic relationship of the B-vitamins with homocysteine, studies have also demonstrated inverse associations between the status of the B-vitamins, folate, vitamins B<sub>12</sub> and B<sub>6</sub> and fracture risk in large cohorts of men and women<sup>(29,33–35)</sup>.

Observational studies have also reported the significant associations of homocysteine concentrations and/or B-vitamin status with BMD (or loss of BMD over time; Table 2)<sup>(38–44)</sup>. Evidence from large USA and Norwegian cohorts demonstrated a significant inverse association of homocysteine concentrations with BMD<sup>(40,42)</sup>. Additionally, a recent 3-year longitudinal study in a Korean population reported an accelerated rate of bone loss in a dose-dependent manner with increasing homocysteine concentration, an effect that was shown in men and pre-menopausal (but not post-menopausal) women<sup>(38)</sup>. In contrast to the latter study that showed no homocysteine relationship in post-menopausal women, Zhu *et al.* in 2009 reported that high homocysteine concentrations were associated with greater bone loss after 4 years in 1213 post-menopausal Australian women<sup>(39)</sup>. Perhaps these apparently conflicting findings might be explained by the larger sample size (*n* 1213) and older age of the Australian women (mean age 75 years) compared with the much smaller sample (*n* 138) of younger (mean age 56 years) post-menopausal Korean women, as well as a longer duration of follow-up

in the Australian study<sup>(38,39)</sup>. In terms of the B-vitamins and BMD, analysis of the Hordaland Homocysteine Study found low plasma folate to be associated with low BMD among Norwegian women<sup>(40)</sup>. Furthermore, the analysis of data from the Framingham Offspring Osteoporosis Study (*n* 2576), a large USA cohort, demonstrated a relationship between low vitamin B<sub>12</sub> status and low BMD<sup>(43)</sup>. Findings from the USA National Health and Nutrition Examination Survey (*n* 1550), also demonstrated that poorer vitamin B<sub>12</sub> (but not folate) status was associated with lower BMD<sup>(42)</sup>. Additionally, a study of 714 older American men and women showed that the participants with deficient plasma vitamin B<sub>6</sub> concentrations (<20 nmol/l) had greater mean annual bone loss than those with normal B<sub>6</sub> concentrations<sup>(41)</sup>.

Some studies, however, have not reported associations between B-vitamins status (and/or homocysteine) and BMD<sup>(45)</sup>, suggesting that the increased osteoporotic fracture risk may be independent of an effect on BMD. Indeed, Van Meurs *et al.*<sup>(36)</sup> found a significant increase in fracture risk associated with the highest (compared with the lowest) quartile of homocysteine concentrations, but no significant differences in BMD values across homocysteine quartiles. Conversely, some studies have found an association of B-vitamin biomarkers with BMD but not with fracture risk. For example, the analysis of an Australian population by Zhu *et al.* demonstrated a significant association of homocysteine with BMD but not with fracture risk; although the latter study, however, may have lacked sufficient statistical power to observe an effect on fracture<sup>(39)</sup>. Additionally, some studies have found an effect on bone (through fracture risk and/or BMD) for folate but not for vitamin B<sub>12</sub><sup>(33,44)</sup> or an effect for vitamin B<sub>12</sub> but not for folate<sup>(42)</sup>. Perhaps any beneficial effect of the B-vitamins may be the most evident in those with compromised status, and therefore the B-vitamin (i.e. folate or vitamin B<sub>12</sub>) that emerges as a risk factor may be more reflective

**Table 3.** The relationship between the 677C→T polymorphism in *MTHFR* and bone health outcomes bone mineral density (BMD) and fracture risk

Author, Country	Sample size, age, gender	Design	Main findings; risk of fracture (95 % CI)
Zhu <i>et al.</i> <sup>(39)</sup> , Australia	<i>n</i> 1213, 70–85 years, female	Cohort study	No relationship between the polymorphism and BMD or fracture, even after stratification by dietary folate, riboflavin and erythrocyte folate
Yazdanpanah <i>et al.</i> <sup>(47)</sup> , The Netherlands	<i>n</i> 5035, ≥55 years, male/female	Cohort study	In the lowest quartile of riboflavin intake, RR 1.80 (1.20, 2.90) and 2.60 (1.30, 5.10) for osteoporotic and fragility fracture, respectively, in women with TT compared with CC genotype
Hong <i>et al.</i> <sup>(48)</sup> , China	<i>n</i> 1899, mean 54 years, female	Cohort study	RR 2.50 (1.20, 4.90) in the CT/TT genotype compared with the CC genotype. No relationship between the polymorphism and BMD
Abrahamsen <i>et al.</i> <sup>(49)</sup> , Denmark	<i>n</i> 1700, mean 50 years, female	Cohort study	BMD associated with the TT genotype in the lowest quartile of riboflavin intake. Similar threshold effects were shown for folate, vitamins B <sub>12</sub> and B <sub>6</sub>
MacDonald <i>et al.</i> <sup>(50)</sup> , UK	<i>n</i> 1241, 45–54 years, female	Cohort study	A significant interaction among quartile of energy-adjusted riboflavin intake, the TT genotype, and BMD ( <i>P</i> =0.01 for baseline femoral neck, <i>P</i> =0.02 at follow-up)
McLean <i>et al.</i> <sup>(51)</sup> , USA	<i>n</i> 1632, mean 59 years, male/female	Cohort study	Individuals with the TT genotype and low folate status had lower BMD than those with the TT genotype and higher folate status
Abrahamsen <i>et al.</i> <sup>(52)</sup> , Denmark	<i>n</i> 1748, mean 51 years, female	Prospective study	The TT genotype was associated with significantly lower BMD and a 2-fold increase in fracture risk
Miyao <i>et al.</i> <sup>(53)</sup> , Japan	<i>n</i> 307, 46–91 years, female	Cohort study	BMD significantly lower in individuals with the TT genotype compared with the CC genotype ( <i>P</i> <0.05)

MTHFR, methylenetetrahydrofolate reductase; RR, relative risk.

The TT and CT genotypes refer to individuals homozygous and heterozygous for the 677C→T polymorphism in *MTHFR* respectively, whereas the CC genotype refers to homozygosity for the wild type.

of the presence of sub-optimal vitamin status in the population being studied. For instance, folate status may vary greatly between populations dependent on whether the folic acid fortification policy in place is mandatory (e.g. USA), voluntary (e.g. most European countries) or not permitted on any basis (e.g. Scandinavia). Apart from differences in the vitamin status, disparities in findings between studies may reflect fundamental differences in the populations under investigation including, although not limited to, differences in ethnicity, sex, age and menopausal status. Furthermore, methodological constraints pertaining to sample size, inclusion and exclusion criteria, methods of measuring B-vitamin status (such as the use of dietary intake data as opposed to more robust blood biomarker measures) and choice of outcome measures, may also contribute to inconsistent findings among studies<sup>(46)</sup>.

#### Genetic evidence

Epidemiological studies investigating the relationship between the *MTHFR* 677C→T polymorphism and bone health add further evidence to support the view that impaired folate metabolism (and the related phenotypes of elevated homocysteine and lower folate concentrations<sup>(19,20)</sup>) may be implicated in adverse outcomes (Table 3)<sup>(39,47–53)</sup>.

Convincingly evidence from a recent meta-analysis of twenty studies (3525 cases and 17909 controls) found that the 677C→T polymorphism was associated with BMD at all measured sites, and with a 23% increased risk for all fractures in individuals with the *MTHFR* 677TT genotype compared with those with the CT or CC genotypes<sup>(13)</sup>. In 2000, the first report

linking the 677C→T polymorphism in *MTHFR* with low BMD was published. This study of 307 healthy post-menopausal Japanese women demonstrated that those with the TT genotype (18.6% of participants) had lower BMD than those with the CC genotype<sup>(53)</sup>. Confirming these findings in a European population, the Danish Osteoporosis Prevention Study demonstrated that among 1748 post-menopausal Danish women, BMD at the spine and hip were significantly lower, and fracture incidence more than two times greater, in individuals with the TT genotype (affecting 8.7% of participants) compared with the CT or CC genotypes<sup>(52)</sup>. One subsequent study reported that individuals with the TT genotype and low folate status (<9 nmol/l), had a lower BMD compared with those with the CC or CT genotypes and low folate status, suggesting an important gene–nutrient interaction<sup>(51)</sup>. Furthermore, Gjesdal *et al.* in 2007 reported an almost 3-fold increased risk of fracture among Norwegian men and women with the TT genotype and low folate status compared with those with the TT genotype and high folate status<sup>(33)</sup>.

Considering that riboflavin plays an integral role in homocysteine metabolism specifically in those with the *MTHFR* 677TT genotype<sup>(21)</sup>, riboflavin intakes have also been investigated in relation to this polymorphism and bone health. In a longitudinal study, involving a subset of 1241 Scottish women from the Aberdeen Osteoporosis Screening Study, low riboflavin intake in combination with the TT genotype had an adverse effect on femoral neck BMD, at baseline and after a mean follow-up of 6.6 years<sup>(50)</sup>. In support of these findings, further analysis of the Danish Osteoporosis Prevention Study cohort concluded that the BMD in individuals with the TT genotype was only significantly reduced



with low dietary intakes of several B-vitamins including folate, B<sub>12</sub>, B<sub>6</sub> and riboflavin<sup>(49)</sup>. In terms of fracture risk, evidence from the Rotterdam Study (*n* 5035) demonstrated that women with the TT genotype in the lowest quartile of riboflavin intakes had 1.8 times greater risk of osteoporotic fracture, and 2.6 times greater risk of fragility fracture (defined as a fracture at the hip, pelvis or proximal humerus), than those in the same quartile of riboflavin intakes with the CC genotype<sup>(47)</sup>. Such findings provide evidence to support a detrimental effect of the polymorphism combined with low B-vitamin intakes on robust bone health outcomes (i.e. BMD and fracture risk), and indicate that B-vitamins may have the potential to modulate any negative effect of this polymorphism on bone health.

To date the majority of bone studies that have considered gene–nutrient interactions have stratified B-vitamin status using dietary intake data, which are prone to a number of sources of error<sup>(39,48)</sup>. For instance, Hong *et al.* in 2007 reported an increased fracture risk associated with the *MTHFR* 677TT genotype, but no effect of the polymorphism on BMD, even after stratification using food groups representative of B-vitamin intakes<sup>(48)</sup>. Additionally Zhu *et al.* in 2009 failed to find an interactive effect of the polymorphism combined with low B-vitamin intakes on BMD or indeed fracture risk<sup>(39)</sup>. Perhaps these null findings might be explained by the inadequacy of B-vitamin intakes to accurately represent B-vitamin status. Other factors, such as differences in ethnicity (considerable variation in the frequency of this polymorphism between populations) and variation in the age of the populations investigated, may also contribute to inconsistencies among studies. Unfortunately, however, a recent meta-analysis showing an association between the *MTHFR* 677TT genotype and BMD and fracture risk, did not address any potential interactive effects of the polymorphism with low B-vitamin status and/or intakes, as most of the studies included did not provide the relevant data to allow this sub-analysis to be performed<sup>(13)</sup>.

#### *Randomised controlled trials*

Evidence in the form of randomised controlled trials (RCT) is limited. One notable RCT, however, found a 75% reduction in the risk of hip fractures among 628 post-stroke Japanese patients in response to combined folic acid and vitamin B<sub>12</sub> supplementation for 2 years, despite no statistical differences in the number of falls experienced in both the treatment and placebo groups<sup>(54)</sup>. Conversely one RCT investigating osteoporotic fracture in stroke patients treated with B-vitamins for more than 2 years, and performed as part of the VITATOPS (VITamins to Prevent Stroke) study, reported no benefit of B-vitamin treatment on osteoporotic fracture<sup>(55)</sup>. As acknowledged by the authors however, this trial was insufficiently powered to detect any potential beneficial effect due to the small number of fracture events<sup>(55)</sup>. Another RCT, using participants with pre-existing CVD from the Heart Outcomes Prevention Evaluation 2 trial, failed to find a beneficial effect of

B-vitamin supplementation on fracture risk<sup>(56)</sup>. It is important to note however, that the folate levels were approximately five times higher in the Heart Outcomes Prevention Evaluation 2 trial participants than in the Japanese stroke patients and so perhaps additional folate was unlikely to confer any further benefit to these individuals<sup>(56)</sup>. It is possible that certain B-vitamins, particularly folate in countries with no folic acid fortification policy, can exert protective effects on bone health that are related to, or independent of, their homocysteine lowering effects.

#### **Potential mechanisms linking B-vitamin biomarkers with bone**

There is currently no clear mechanism to explain the potential role of the B-vitamins and/or homocysteine in bone health, however various hypotheses have been investigated.

#### *Evidence to support an effect of homocysteine on bone*

Evidence from a rat model suggests that hyperhomocysteinemia induces accumulation of collagen-bound homocysteine in bone resulting in decreased bone strength<sup>(57)</sup>. In support of this relationship, an early hypothesis by McKusick suggested homocysteine had a detrimental effect on bone strength by way of disrupting collagen cross-linking (integral to bone strength)<sup>(58)</sup>. Consistent with McKusick's theory, an *in vitro* study by Kang & Trelstad in 1973, found that homocysteine interfered with collagen cross-links from purified rat skin collagen<sup>(59)</sup> and this is supported by a recent cell study demonstrating a mechanistic effect of homocysteine on lysyl oxidase (an enzyme required for collagen cross-linking)<sup>(60)</sup>. Additionally, a small study in homocystinuric patients (*n* 10) and controls provided evidence that premature osteoporosis among patients could be explained by disruption of collagen cross-linking as opposed to a reduction in collagen syntheses<sup>(58)</sup>. A case–control study by Saito *et al.* in 2006 comparing bone biopsies from twenty-five hip fracture cases and twenty-five post-mortem age- and sex-matched controls found significantly higher homocysteine concentrations, lower vitamin B<sub>6</sub> concentrations and lower collagen cross-links in the hip fracture cases compared with controls<sup>(61)</sup>. However, while convincing, evidence to support a role for elevated homocysteine in the reduction of collagen cross-links as a causal mechanism in fracture risk remains inconclusive.

*In vitro* studies have also investigated a potential effect of homocysteine on bone turnover. Evidence exists to support a stimulatory effect of mildly elevated homocysteine concentrations (as low as 10 μmol/l) on osteoclastic activity, thereby increasing bone resorption<sup>(62,63)</sup> and an inhibitory effect of homocysteine on bone formation<sup>(64)</sup>. Consistent with such *in vitro* evidence, plasma homocysteine was shown to correlate positively with markers of bone resorption, but not bone formation, in peri- and post-menopausal women<sup>(65)</sup>. Further

observational evidence to support a relationship between homocysteine and markers of bone resorption has been described<sup>(66)</sup>.

More recently, evidence from a rat model suggests homocysteine induces a reduced bone blood flow and therefore ability to repair micro-damage in bone<sup>(67)</sup>. Additionally, evidence to support a relationship between elevated homocysteine and impaired physical function suggests that homocysteine could act independently of bone, by increasing fracture risk through poor physical ability<sup>(68,69)</sup>.

#### *Evidence to support an effect of folate on bone*

While folate has been linked to BMD and a reduced fracture risk<sup>(54,70)</sup>, there is limited evidence to support a direct mechanistic effect of folate on bone, although one study reported a reduced trabecular thickness of bone in individuals with low folate status *v.* those with higher status<sup>(71)</sup>. Folate could have an indirect role on bone remodelling cells via its metabolic link (as a methyl source) to the methylation of DNA, proteins and other molecules and there is evidence, albeit somewhat inconsistent, to support a reduced methylation capacity as a pathomechanism responsible for poor bone health<sup>(57,72–74)</sup>. Alternatively, folate may exert a protective effect on bone through its homocysteine lowering effect<sup>(54)</sup>.

#### *Evidence to support an effect of vitamins B<sub>12</sub> and B<sub>6</sub> on bone*

Findings from a small clinical trial showed significantly lower alkaline phosphatase (a marker of bone formation) in vitamin B<sub>12</sub> deficient patients compared with the controls, and a subsequent rise in alkaline phosphatase following B<sub>12</sub> supplementation in the deficient patients but not in the controls<sup>(75)</sup>. Additionally, evidence from an *in vitro* study showed a stimulatory effect of vitamin B<sub>12</sub> on alkaline phosphatase<sup>(76)</sup>. Such findings suggest a protective effect of vitamin B<sub>12</sub> on bone formation. However, a large retrospective study of 9506 pernicious anaemia patients in the UK, which showed a 74% increased fracture risk in patients *v.* healthy controls, reported that the increased fracture risk remained after correction of the vitamin B<sub>12</sub> deficiency, thereby suggesting a detrimental effect of pernicious anaemia on bone not related to low vitamin B<sub>12</sub> status<sup>(77)</sup>. Low vitamin B<sub>6</sub> status was found to be associated with decreased concentrations of bone formation markers in an animal model<sup>(78)</sup>. However, trials involving supplementation of folate, vitamins B<sub>12</sub> and B<sub>6</sub>, and thereby lowering homocysteine concentrations, have failed to find a beneficial effect on bone turnover; suggesting that if a benefit of B-vitamin supplementation, or homocysteine lowering, on bone health exists, it is independent of any effect on bone turnover<sup>(79,80)</sup>. Interestingly, vitamin B<sub>6</sub> acts as an essential co-enzyme for lysyl oxidase, an enzyme required for collagen cross-linking; suggesting that low vitamin B<sub>6</sub> may be detrimental for collagen cross-linking and result in poorer bone mechanical performance<sup>(81,82)</sup>.

It is apparent that the interrelationship between the B-vitamins, homocysteine and bone health is complicated, and probably multi-factorial, with further trials needed to fully elucidate potential mechanisms.

### **Bone health in coeliac disease**

#### *Coeliac disease*

Coeliac disease (CD) is a common autoimmune, inflammatory condition in genetically predisposed individuals and is induced by the ingestion of 'gluten', a generic term used to describe the disease activating proteins and peptides found in wheat, barley, rye and sometimes in oats<sup>(83)</sup>. The mainstay treatment of CD is the gluten-free diet. Untreated CD is characterised by villous atrophy, leading to malabsorption of nutrients, and is responsible for many of the traditional clinical manifestations of disease including diarrhoea, weight loss and vitamin deficiencies in iron, folate and calcium. The gold standard diagnosis of CD is based on the presence of villous atrophy (or more mild features of enteropathy) as determined by a well-orientated biopsy of the small intestine, with the presence of autoantibodies to gluten (endomysial antibodies and tissue transglutaminase antibodies) being screened for in the first instance<sup>(83)</sup>.

#### *Osteoporosis in coeliac disease*

CD patients are well known to be at a higher risk of osteoporosis compared with the general population. A recent review reported that 38–72% of CD patients have significantly lower BMD at presentation than non-CD populations matched for age and sex<sup>(2,84)</sup>. The gluten-free diet is expected to alleviate mucosal damage, and the corresponding malabsorption of calcium and other nutrients, and thereby results in higher BMD<sup>(85)</sup>. The evidence, however, suggests that the CD patients still fail to achieve the BMD of healthy controls<sup>(86)</sup>. Additionally, a meta-analysis involving eight studies and approximately 21 000 CD patients reported a 43% increased fracture risk among patients compared with controls<sup>(87)</sup>. Although the aetiology of poor bone health in CD is unclear, various factors, including calcium and vitamin D malabsorption, resultant secondary hyperparathyroidism and the inability to reach peak bone mass in young adulthood, are reported to play a role<sup>(84)</sup>. More recently, a negative impact of pro-inflammatory markers (such as TNF- $\alpha$  and interferon- $\gamma$ ), which are chronically released during gut inflammation and associated with bone loss, are also believed to contribute to poor bone health in CD<sup>(88)</sup>. Additionally, a lower ratio of osteoprotegerin (known to protect against excessive bone resorption) to receptor activator of NF- $\kappa$ B-ligand (RANKL; associated with bone resorption activity) found in treated CD patients (with recovered mucosa) compared with healthy controls, and a positive correlation between the osteoprotegerin :RANKL ratio and BMD, suggests a damaging effect of a low ratio on BMD even in treated CD patients<sup>(89)</sup>.

It is also possible that nutrients not typically linked to bone health, such as the B-vitamins, contribute a



protective effect on bone in these patients. Low folate and vitamin B<sub>12</sub> status, accompanied by elevated concentrations of homocysteine, are well described among CD patients<sup>(90)</sup>. Given the emergence of evidence to support a protective role of B-vitamins and a detrimental effect of homocysteine on bone health, it is possible that B-vitamin inadequacies and/or elevated concentrations of homocysteine, play a role in osteoporosis development in CD. Indeed, given the much higher incidence both of osteoporosis and B-vitamin deficiencies, CD patients comprise a unique 'at-risk' group to investigate in terms of a potential link between B-vitamins and bone health. A 2-year RCT supplementing CD patients with folic acid and vitamin B<sub>12</sub> and measuring BMD (by dual-energy X-ray absorptiometry scans) pre- and post-intervention is currently underway at our centre with results expected in 2014. This trial will likely shed light as to whether a causal relationship between the B-vitamins and/or homocysteine and BMD exists.

### Conclusion and future work

There is consistent observational evidence of an association of homocysteine related B-vitamins with bone health. This epidemiological evidence is further strengthened by genetic studies showing an important association between the common *MTHFR* 677C→T polymorphism and osteoporosis risk. However, confirmation of a causal link between B-vitamins and bone health from RCT is lacking. Further trials to investigate fracture risk or other robust outcomes such as BMD should focus on various 'at-risk' population groups (such as CD patients, post-menopausal women or individuals with the *MTHFR* 677TT genotype). Such evidence will confirm whether low B-vitamin status is causally associated with osteoporosis risk and whether there are beneficial effects of B-vitamin supplementation in bone health.

### Acknowledgements

None.

### Financial Support

This work was supported by funding from the Northern Ireland Department for Employment and Learning which funded the PhD studentship for M. M. C.

### Conflicts of Interest

None.

### Authorship

M. M. C. drafted the manuscript. H. McN., M. W., J. J. S. and W. D. critically revised the manuscript for important intellectual content. All authors have read and approved the final manuscript.

### References

1. Peck WA, Burckhardt P, Christiansen C *et al.* (1993) Consensus development conference – diagnosis, prophylaxis, and treatment of osteoporosis. *Am J Med* **94**, 646–650.
2. Strom O, Borgstrom F, Kanis JA *et al.* (2011) Osteoporosis: burden, health care provision and opportunities in the EU: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). *Arch Osteoporos* **6**, 59–155.
3. Van Staa TP, Dennison EM, Leufkens HGM *et al.* (2001) Epidemiology of fractures in England and Wales. *Bone* **29**, 517–522.
4. Prentice A. (2001) The relative contribution of diet and genotype to bone development. *Proc Nutr Soc* **60**, 45–52.
5. Kanis JA, McCloskey EV, Johansson H *et al.* (2013) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. *Osteoporos Int* **24**, 23–57.
6. Kanis JA, Alexeeva L, Bonjour JP *et al.* (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis – synopsis of a who report. *Osteoporos Int* **4**, 368–381.
7. Cummings SR, Browner W, Cummings SR *et al.* (1993) Bone density at various sites for prediction of hip fractures. *Lancet* **341**, 72–75.
8. Marshall D, Johnell O & Wedel H (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. *BMJ* **312**, 1254–1259.
9. Kanis JA, McCloskey EV, Johansson H *et al.* (2010) Development and use of FRAXA (R) in osteoporosis. *Osteoporos Int* **21**, 407–413.
10. Michaëlsson K, Melhus H, Ferm H *et al.* (2005) Genetic liability to fractures in the elderly. *Arch Intern Med* **165**, 1825–1830.
11. Tang BMP, Eslick GD, Nowson C *et al.* (2007) Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. *Lancet* **370**, 657–666.
12. van Wijngaarden JP, Doets EL, Szczecinska A *et al.* (2013) Vitamin B<sub>12</sub>, folate, homocysteine, and bone health in adults and elderly people: a systematic review with meta-analyses. *J Nutr Metab* **2013**, 486186.
13. Wang H & Liu C (2012) Association of *MTHFR* C667T polymorphism with bone mineral density and fracture risk: an updated meta-analysis. *Osteoporos Int* **23**, 2625–2634.
14. McKinley MC, McNulty H, McPartlin J *et al.* (2001) Low-dose vitamin B-6 effectively lowers fasting plasma homocysteine in healthy elderly persons who are folate and riboflavin replete. *Am J Clin Nutr* **73**, 759–764.
15. Homocysteine Lowering Trialists' Collaboration (1998) Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. *BMJ* **316**, 894–898.
16. Schwahn B & Rozen R (2001) Polymorphisms in the methylenetetrahydrofolate reductase gene: clinical consequences. *Am J Pharmacogenomics* **1**, 189–201.
17. Yamada K, Chen Z, Rozen R *et al.* (2001) Effects of common polymorphisms on the properties of recombinant human methylenetetrahydrofolate reductase. *Proc Natl Acad Sci USA* **98**, 14853–14858.
18. Malinow M, Bostom A & Krauss R (1999) Homocyst(e)ine, diet, and cardiovascular diseases – a statement for





- healthcare professionals from the Nutrition Committee, American Heart Association. *Circulation* **99**, 178–182.
19. Frosst P, Blom HJ, Milos R *et al.* (1995) A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. *Nat Genet* **10**, 111–113.
  20. Molloy A, Daly S, Mills J *et al.* (1997) Thermolabile variant of 5, 10-methylenetetrahydrofolate reductase associated with low red-cell folates: implications for folate intake recommendations. *Lancet* **349**, 1591–1593.
  21. McNulty H, Dowe le RC, Strain JJ *et al.* (2006) Riboflavin lowers homocysteine in individuals homozygous for the MTHFR 677C->T polymorphism. *Circulation* **113**, 74–80.
  22. Botto LD & Yang Q (2000) 5, 10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: a HuGE review. *Am J Epidemiol* **151**, 862–877.
  23. Wilcken B, Bamforth F, Li Z *et al.* (2003) Geographical and ethnic variation of the 677C>T allele of 5, 10 methylenetetrahydrofolate reductase (MTHFR): findings from over 7000 newborns from 16 areas world wide. *J Med Genet* **40**, 619–625.
  24. Refsum H, Smith A, Ueland P *et al.* (2004) Facts and recommendations about total homocysteine determinations: an expert opinion. *Clin Chem* **50**, 3–32.
  25. Mudd S, Skovby F, Levy H *et al.* (1985) The natural-history of homocystinuria due to cystathionine beta-synthase deficiency. *Am J Hum Genet* **37**, 1–31.
  26. Maron BA & Loscalzo J (2009) The treatment of hyperhomocysteinemia. *Annu Rev Med* **60**, 39–54.
  27. Eastell R, Vieira N, Yerger A *et al.* (1992) Pernicious-anemia as a risk factor for osteoporosis. *Clin Sci* **82**, 681–685.
  28. Goerss J, Kim C, Atkinson E *et al.* (1992) Risk of fractures in patients with pernicious-anemia. *J Bone Miner Res* **7**, 573–579.
  29. Dai Z, Wang R, Ang LW *et al.* (2013) Dietary B vitamin intake and risk of hip fracture: the Singapore Chinese Health Study. *Osteoporos Int* **24**, 2049–2059.
  30. Yang J, Hu X, Zhang Q *et al.* (2012) Homocysteine level and risk of fracture: a meta-analysis and systematic review. *Bone* **51**, 376–382.
  31. Enneman AW, Swart KM, van Wijngaarden JP *et al.* (2012) Association between plasma homocysteine and bone density and quality parameters in the elderly. *Bone* **50**, S134–S134.
  32. LeBoff MS (2009) Homocysteine levels and risk of hip fracture in postmenopausal women. *J Clin Endocrinol Metab* **94**, 1207–1213.
  33. Gjesdal C, Voliset S, Ueland P *et al.* (2007) Plasma homocysteine, folate, and vitamin B sub(12) and the risk of hip fracture: the Hordaland Homocysteine study. *J Bone Miner Res* **22**, 747–756.
  34. Yazdanpanah N, Zillikens MC, Rivadeneira F *et al.* (2007) Effect of dietary B vitamins on BMD and risk of fracture in elderly men and women: the Rotterdam study. *Bone* **41**, 987–994.
  35. Dhonukshe-Rutten R, Pluijm S, de Groot L *et al.* (2005) Homocysteine and vitamin B-12 status relate to bone turnover markers, broadband ultrasound attenuation, and fractures in healthy elderly people. *J Bone Miner Res* **20**, 921–929.
  36. van Meurs JBJ, Dhonukshe-Rutten RAM, Pluijm SMF *et al.* (2004) Homocysteine levels and the risk of osteoporotic fracture. *N Engl J Med* **350**, 2033–2041.
  37. McLean RR, Jacques PF, Selhub J *et al.* (2004) Homocysteine as a predictive factor for hip fracture in older persons. *N Engl J Med* **350**, 2042–2049.
  38. Kim B, Koh J, Ahn SH *et al.* (2013) High serum total homocysteine levels accelerate hip bone loss in healthy premenopausal women and men. *Bone* **52**, 56–62.
  39. Zhu K, Beilby J, Dick IM *et al.* (2009) The effects of homocysteine and MTHFR genotype on hip bone loss and fracture risk in elderly women. *Osteoporos Int* **20**, 1183–1191.
  40. Gjesdal CG, Vollset SE, Ueland PM *et al.* (2006) Plasma total homocysteine level and bone mineral density – the Hordaland homocysteine study. *Arch Intern Med* **166**, 88–94.
  41. McLean RR, Jacques PF, Selhub J *et al.* (2008) Plasma B Vitamins, Homocysteine, and their relation with bone loss and hip fracture in elderly men and women. *J Clin Endocrinol Metab* **93**, 2206–2212.
  42. Morris M, Jacques P & Selhub J (2005) Relation between homocysteine and B-vitamin status indicators and bone mineral density in older Americans. *Bone* **37**, 234–242.
  43. Tucker KL, Hannan MT, Qiao N *et al.* (2005) Low plasma vitamin B<sub>12</sub> is associated with lower BMD: the Framingham Osteoporosis study. *J Bone Miner Res* **20**, 152–158.
  44. Cagnacci A, Baldassari F, Rivolta G *et al.* (2003) Relation of homocysteine, folate, and vitamin B<sub>12</sub> to bone mineral density of postmenopausal women. *Bone* **33**, 956–959.
  45. Rumbak I, Zizic V, Sokolic L *et al.* (2012) Bone mineral density is not associated with homocysteine level, folate and vitamin B-12 status. *Arch Gynecol Obstet* **285**, 991–1000.
  46. Herrmann M, Peter Schmidt J, Umanskaya N *et al.* (2007) The role of hyperhomocysteinemia as well as folate, vitamin B<sub>(6)</sub> and B<sub>(12)</sub> deficiencies in osteoporosis: a systematic review. *Clin Chem Lab Med : CCLMIFESCC* **45**, 1621–1632.
  47. Yazdanpanah N, Uitterlinden AG, Zillikens MC *et al.* (2008) Low dietary riboflavin but not folate predicts increased fracture risk in postmenopausal women homozygous for the MTHFR 677 T allele. *J Bone Miner Res* **23**, 86–94.
  48. Hong X, Hsu Y, Terwedow H *et al.* (2007) Association of the methylenetetrahydrofolate reductase C677T polymorphism and fracture risk in Chinese postmenopausal women. *Bone* **40**, 737–742.
  49. Abrahamsen B, Madsen JS, Tofteng CL *et al.* (2005) Are effects of MTHFR (C677T) genotype on BMD confined to women with low folate and riboflavin intake? Analysis of food records from the Danish osteoporosis prevention study. *Bone* **36**, 577–583.
  50. Macdonald HM, McGuigan FE, Fraser WD *et al.* (2004) Methylenetetrahydrofolate reductase polymorphism interacts with riboflavin intake to influence bone mineral density. *Bone* **35**, 957–964.
  51. McLean RR, Karasik D, Selhub J *et al.* (2004) Association of a common polymorphism in the methylenetetrahydrofolate reductase (MTHFR) gene with bone phenotypes depends on plasma folate status. *J Bone Miner Res* **19**, 410–418.
  52. Abrahamsen B, Madsen JS, Tofteng CL *et al.* (2003) A common methylenetetrahydrofolate reductase (C677T) polymorphism is associated with low bone mineral density and increased fracture incidence after menopause: longitudinal data from the Danish osteoporosis prevention study. *J Bone Miner Res* **18**, 723–729.
  53. Miyao M, Morita H, Hosoi T *et al.* (2000) Association of methylenetetrahydrofolate reductase (MTHFR) polymorphism with bone mineral density in postmenopausal Japanese women. *Calcif Tissue Int* **66**, 190–194.



54. Sato Y, Honda Y, Iwamoto J *et al.* (2005) Effect of folate and mecobalamin on hip fractures in patients with stroke: a randomized controlled trial. *JAMA* **293**, 1082–1088.
55. Gommans J, Yi Q, Eikelboom JW *et al.* (2013) The effect of homocysteine-lowering with B-vitamins on osteoporotic fractures in patients with cerebrovascular disease: substudy of VITATOPS, a randomised placebo-controlled trial. *BMC Geriatr* **13**, 88.
56. Sawka AM, Ray JG, Yi Q *et al.* (2007) Randomized clinical trial of homocysteine level lowering therapy and fractures. *Arch Int Med* **167**, 2136–2139.
57. Herrmann M, Tami A, Wildemann B *et al.* (2009) Hyperhomocysteinemia induces a tissue specific accumulation of homocysteine in bone by collagen binding and adversely affects bone. *Bone* **44**, 467–475.
58. Lubec B, Fang-Kircher S, Lubec T *et al.* (1996) Evidence for McKusick's hypothesis of deficient collagen cross-linking in patients with homocystinuria. *Biochim Biophys Acta* **1315**, 159–162.
59. Kang A & Trelstad R (1973) Collagen defect in Homocystinuria. *J Clin Invest* **52**, 2571–2578.
60. Thaler R, Agsten M, Spitzer S *et al.* (2011) Homocysteine suppresses the expression of the collagen cross-linker lysyl oxidase involving IL-6, Fli1, and epigenetic DNA methylation. *J Biol Chem* **286**, 5578–5588.
61. Saito M, Fujii K & Marumo K (2006) Degree of mineralization-related collagen crosslinking in the femoral neck cancellous bone in cases of hip fracture and controls. *Calcif Tissue Int* **79**, 160–168.
62. Herrmann M, Widmann T, Colaianni G *et al.* (2005) Increased osteoclast activity in the presence of increased homocysteine concentrations. *Clin Chem* **51**, 2348–2353.
63. Koh J, Lee Y, Kim Y *et al.* (2006) Homocysteine enhances bone resorption by stimulation of osteoclast formation and activity through increased intracellular ROS generation. *J Bone Miner Res* **21**, 1003–1011.
64. Kim DJ, Koh J, Lee O *et al.* (2007) Homocysteine enhances apoptosis in human bone marrow stromal cells (vol 39, pg 582, 2006). *Bone* **40**, 554–555.
65. Herrmann M, Kranzlin M, Pape G *et al.* (2005) Relation of homocysteine, biochemical bone markers, and bone mineral density in peri- and postmenopausal women. *Bone* **36**, S338–S338.
66. McLean RR & Hannan MT (2007) B vitamins, homocysteine, and bone disease: epidemiology and pathophysiology. *Curr Osteoporos Rep* **5**, 112–119.
67. Tyagi N, Kandel M, Munjal C *et al.* (2011) Homocysteine mediated decrease in bone blood flow and remodeling: role of folic acid. *J Orthopaed Res* **29**, 1511–1516.
68. van Schoor NM, Swart KMA, Pluijm SMF *et al.* (2012) Cross-sectional and longitudinal association between homocysteine, vitamin B<sub>12</sub> and physical performance in older persons. *Eur J Clin Nutr* **66**, 174–181.
69. Swart KMA, Enneman AW, van Wijngaarden JP *et al.* (2013) Homocysteine and the methylenetetrahydrofolate reductase 677C →T polymorphism in relation to muscle mass and strength, physical performance and postural sway. *Eur J Clin Nutr* **67**, 743–748.
70. Cagnacci A, Bagni B, Zini A *et al.* (2008) Relation of folates, vitamin B<sub>12</sub> and homocysteine to vertebral bone mineral density change in postmenopausal women. A five-year longitudinal evaluation. *Bone* **42**, 314–320.
71. Holstein JH, Herrmann M, Splett C *et al.* (2009) Low serum folate and vitamin B-6 are associated with an altered cancellous bone structure in humans. *Am J Clin Nutr* **90**, 1440–1445.
72. Enneman AW, van der Velde N, de Jonge R *et al.* The association between plasma homocysteine levels, methylation capacity and incident osteoporotic fractures. *Bone* **50**, 1401–1405.
73. Vaes BLT, Lute C, van der Woning SP *et al.* (2010) Inhibition of methylation decreases osteoblast differentiation via a non-DNA-dependent methylation mechanism. *Bone* **46**, 514–523.
74. Holstein JH, Herrmann M, Splett C *et al.* (2011) High bone concentrations of homocysteine are associated with altered bone morphology in humans. *Br J Nutr* **106**, 378–382.
75. Carmel R, Lau K, Baylink D *et al.* (1988) Cobalamin and osteoblast-specific proteins. *N Engl J Med* **319**, 70–75.
76. Kim G, Kim C, Park J *et al.* (1996) Effects of vitamin B-12 on cell proliferation and cellular alkaline phosphatase activity in human bone marrow stromal osteoprogenitor cells and UMR106 osteoblastic cells. *Metab-Clin Exp* **45**, 1443–1446.
77. Merriman NA, Putt ME, Metz DC *et al.* (2010) Hip fracture risk in patients with a diagnosis of Pernicious anemia. *Gastroenterology* **138**, 1330–1337.
78. Masse P, Delvin E, Hauschka P *et al.* (2000) Perturbations in factors that modulate osteoblast functions in vitamin B<sub>6</sub> deficiency. *Can J Physiol Pharmacol* **78**, 904–911.
79. Green T, McMahon J, Skeaff C *et al.* (2007) Lowering homocysteine with B vitamins has no effect on biomarkers of bone turnover in older persons: a 2-y randomized controlled trial. *Am J Clin Nutr* **85**, 460–464.
80. Herrmann M, Umanskaya N, Traber L *et al.* (2007) The effect of B-vitamins on biochemical bone turnover markers and bone mineral density in osteoporotic patients: a 1-year double blind placebo controlled trial. *Clin Chem Lab Med* **45**, 1785–1792.
81. Bird T & Levene C (1982) Lysyl oxidase – evidence that pyridoxal-phosphate is a cofactor. *Biochem Biophys Res Commun* **108**, 1172–1180.
82. Masse P, Rinnac C, Yamauchi M *et al.* (1996) Pyridoxine deficiency affects biomechanical properties of chick tibial bone. *Bone* **18**, 567–574.
83. Green PH & Jabri B (2003) Coeliac disease. *Lancet* **362**, 383–391.
84. Larussa T, Suraci E, Nazionale I *et al.* (2012) Bone mineralization in celiac disease. *Gastroenterol Res Pract*. vol. 2012, Article ID 198025. doi:10.1155/2012/198025.
85. Pazianas M, Butcher G, Subhani J *et al.* (2005) Calcium absorption and bone mineral density in celiacs after long term treatment with gluten-free diet and adequate calcium intake. *Osteoporos Int* **16**, 56–63.
86. Corazza G, Disario A, Cecchetti L *et al.* (1995) Bone mass and metabolism in patients with celiac-disease. *Gastroenterology* **109**, 122–128.
87. Olmos M, Antelo M, Vazquez H *et al.* (2008) Systematic review and meta-analysis of observational studies on the prevalence of fractures in coeliac disease. *Dig Liver Dis* **40**, 46–53.
88. Tilg H, Moschen AR, Kaser A *et al.* (2008) Gut, inflammation and osteoporosis: basic and clinical concepts. *Gut* **57**, 684–694.
89. Fiore CE, Pennisi P, Ferro G *et al.* (2006) Altered osteoprotegerin/RANKL ratio and low bone mineral density in celiac patients on long-term treatment with gluten-free diet. *Hormone Metab Res* **38**, 417–422.
90. Dickey W, Ward M, Whittle CR *et al.* (2008) Homocysteine and related B-vitamin status in coeliac disease: effects of gluten exclusion and histological recovery. *Scand J Gastroenterol* **43**, 682–688.